Featured Research

from universities, journals, and other organizations

Parkinson’s patients more likely to stick with certain ‘add-on’ drugs

July 13, 2010
Center for Advancing Health
Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

Related Articles

People with Parkinson's disease often initially experience tremors, stiffness, slowed movement or difficulty with balance and coordination. These symptoms result from the destruction of brain cells that produce dopamine -- an important chemical that transmits nerve impulses.

Many people with Parkinson's start treatment by taking levodopa, which the body converts to dopamine. After a time, however, levodopa alone is not always enough.

The three classes of drugs for add-on treatment are dopamine agonists, which stimulate dopamine receptors in the brain, drugs known as COMT inhibitors and MAOB inhibitors, which slow the breakdown of dopamine in the body.

Of these, dopamine agonists might be most effective, according to a new review.

The irony for patients and doctors alike is that while all of the add-on drugs help improve functional motor skills, they simultaneously might increase numerous other side effects such as dyskinesia, dizziness, sleep disturbances, nausea, constipation and even hallucinations.

Although the risk of side effects increased with all three types of add-on drugs, patients were most likely to continue treatment when they were taking dopamine agonists. This class includes medications such as pramipexole (Mirapex), ropinirole (Requip), cabergoline (Dostinex) and bromocriptine (Parlodel).

"There's a tendency to think that stronger drugs give more adverse effects, but we didn't find that with dopamine agonists," says review co-author Carl E. Clarke, M.D., a neurologist at the University of Birmingham in England. "They seem to be as well tolerated as the other classes, so the results are quite positive in terms of using the agonists ahead of the other two."

Parkinson's disease is a chronic, progressive disorder affecting more than 6 million people worldwide, making it the most common degenerative condition of the brain after Alzheimer's disease. Both illnesses are most common in the elderly, so with an aging U.S. population, their prevalence is likely to increase.

"No treatments have been proven to slow progression of the disease," said William J. Weiner, M.D., director of the Maryland Parkinson's Disease and Movement Disorders Center at the University of Maryland Medical Center. "Yet with treatment to alleviate motor symptoms, most patients can function extremely well for six to 10 years."

Levodopa typically controls symptoms very well for up to five years, but eventually a patient's symptoms start to reappear each day before the next dose is due -- or symptoms might reappear and disappear unpredictably. Patients might also develop dyskinesia, which results in uncontrollable jerking and writhing movements.

Doctors can then add another medication to the levodopa therapy.

"The greater efficacy and reduced likelihood of patient withdrawal with dopamine agonist therapy possibly outweighs the disadvantage of increased side effects," concludes the review. This finding matches Weiner's clinical experience gained from decades of treating people with the disease.

"Most [Parkinson's] patients prefer to have these dyskinesias and other moderate side effects than to have more disabling motor complications like being unable to walk," he says. "Hallucinations may be troublesome and frightening initially, but they are typically benign -- a patient might think he sees a dog -- and people can get used to them."

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates research in all aspects of health care. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing trials on a topic.

This review assessed data from 44 randomized trials involving 8,436 participants. The authors caution, however, that the studies compared each class of drugs against placebo, rather than conducting "head-to-head" comparisons of each class against the others.

This leaves open the possibility that the findings arose not from actual differences in the treatments, but rather from other factors such as differences in the types of people included in the various trials. A large trial featuring direct comparisons of the three drug classes currently is underway in the United Kingdom, Clarke said.

Of the drugs in the COMT inhibitor class, the review suggests that tolcapone (Tasmar) is as effective as the dopamine agonists. However, tolcapone has been linked to a few cases of fatal liver toxicity and can now only be prescribed in the United States with intense monitoring.

"Tolcapone is worth using in patients where [the alternative] is not working well, and we mustn't discount it," Clarke said. "This evidence clearly states that."

The review disclosed that Clarke has received payments for consulting, lectures and travel from Boehringer-Ingelheim, GlaxoSmithKline, Lundbeck, Orion, Teva, UCB, and Valeant.

Story Source:

The above story is based on materials provided by Center for Advancing Health. The original article was written by Laura Kennedy. Note: Materials may be edited for content and length.

Journal Reference:

  1. Stowe et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson΄s disease patients with motor complications. Cochrane Database of Systematic Reviews Reviews, 2010; DOI: 10.1002/14651858.CD007166.pub2

Cite This Page:

Center for Advancing Health. "Parkinson’s patients more likely to stick with certain ‘add-on’ drugs." ScienceDaily. ScienceDaily, 13 July 2010. <www.sciencedaily.com/releases/2010/07/100713214624.htm>.
Center for Advancing Health. (2010, July 13). Parkinson’s patients more likely to stick with certain ‘add-on’ drugs. ScienceDaily. Retrieved January 30, 2015 from www.sciencedaily.com/releases/2010/07/100713214624.htm
Center for Advancing Health. "Parkinson’s patients more likely to stick with certain ‘add-on’ drugs." ScienceDaily. www.sciencedaily.com/releases/2010/07/100713214624.htm (accessed January 30, 2015).

Share This

More From ScienceDaily

More Mind & Brain News

Friday, January 30, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Binge-Watching TV Linked To Loneliness

Binge-Watching TV Linked To Loneliness

Newsy (Jan. 29, 2015) — Researchers at University of Texas at Austin found a link between binge-watching TV shows and feelings of loneliness and depression. Video provided by Newsy
Powered by NewsLook.com
Signs You Might Be The Passive Aggressive Friend

Signs You Might Be The Passive Aggressive Friend

BuzzFeed (Jan. 28, 2015) — "No, I&apos;m not mad. Why, are you mad?" Video provided by BuzzFeed
Powered by NewsLook.com
City Divided: A Look at Model Schools in the TDSB

City Divided: A Look at Model Schools in the TDSB

The Toronto Star (Jan. 27, 2015) — Model schools are rethinking how they engage with the community to help enhance the lives of the students and their parents. Video provided by The Toronto Star
Powered by NewsLook.com
Man Saves Pennies For 65 Years

Man Saves Pennies For 65 Years

Rooftop Comedy (Jan. 26, 2015) — A man in Texas saved every penny he found for 65 years, and this week he finally cashed them in. Bank tellers at Prosperity Bank in Slaton, Texas were shocked when Ira Keys arrived at their bank with over 500 pounds of loose pennies stored in coffee cans. After more than an hour of sorting and counting, it turned out the 81 year-old was in possession of 81,600 pennies, or $816. And he&apos;s got more at home! Video provided by Rooftop Comedy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins